// App-Quantinova.ai

604 : Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies

Researchers

Presenter

  • Philip J Mease

Principal Investigators

  • Dafna D Gladman

  • Juan J. Gomez-Reino

  • Stephen Hall

  • Arthur Kavanaugh

  • Eric Lespessailles

  • Georg Schett

  • Maria Paris

  • Lichen Teng

  • Jrgen Wollenhaupt

Medical Centers

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Toronto Western Research Institute, Toronto, Ontario, Canada

  • Hospital Universitario Clinico de Santiago, Santiago de Compostela, Spain

  • Monash University, CabriniHealth, Melbourne, Australia

  • University of California, San Diego School of Medicine, La Jolla, CA

  • Universite dOrleans, Orleans, France

  • Friedrich Alexander University Erlangen-Nurnberg, Nurnberg, Germany

  • Celgene Corporation, Summit, NJ

  • Schon Klinik Hamburg Eilbek, Klinik fur Rheumatologie, Hamburg, Germany

Locations

  • United States

  • Canada

  • Spain

  • Australia

  • France

  • Germany

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved